Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

ATI-450 Plus MTX rispetto a Placebo Plus MTX in pazienti con AR attiva da moderata a grave

2 settembre 2026 aggiornato da: Aclaris Therapeutics, Inc.

ATI-450 Plus MTX rispetto a Placebo Plus MTX in pazienti con AR attiva da moderata a grave che hanno avuto una risposta inadeguata al solo MTX

This study evaluates ATI-450 plus MTX versus placebo plus MTX in participants with moderate to severe active RA who have had an inadequate response to MTX alone.

Panoramica dello studio

Descrizione dettagliata

This is a Phase 2b, randomized, multicenter, double-blind, parallel group, placebo controlled, dose ranging study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of ATI-450 plus MTX versus placebo plus MTX in participants with moderate to severe active RA who have had an inadequate response to MTX alone.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

251

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Pleven, Bulgaria, 5800
        • Aclaris Investigational Site
      • Plovdiv, Bulgaria, 4000
        • Aclaris Investigational Site
      • Plovdiv, Bulgaria, 4001
        • Aclaris Investigational Site
      • Plovdiv, Bulgaria, 4002
        • Aclaris Investigational Site
      • Plovdiv, Bulgaria, 4004
        • Aclaris Investigational Site
      • Sofia, Bulgaria, 1336
        • Aclaris Investigational Site
      • Sofia, Bulgaria, 1431
        • Aclaris Investigational Site
      • Sofia, Bulgaria, 1606
        • Aclaris Investigational Site
      • Varna, Bulgaria, 9000
        • Aclaris Investigational Site
      • Brno, Cechia, 615 00
        • Aclaris Investigational Site
      • Hlučín, Cechia, 748 01
        • Aclaris Investigational Site
      • Ostrava, Cechia, 702 00
        • Aclaris Investigational Site
      • Pardubice, Cechia, 530 02
        • Aclaris Investigational Site
      • Prague, Cechia, 128 50
        • Aclaris Investigational Site
      • Prague, Cechia, 140 00
        • Aclaris Investigational Site
      • Uherské Hradiště, Cechia, 686 01
        • Aclaris Investigational Site
      • Bialystok, Polonia, 15-297
        • Aclaris Investigational Site
      • Bialystok, Polonia, 15-879
        • Aclaris Investigational Site
      • Dąbrówka, Polonia, 62-069
        • Aclaris Investigational Site
      • Krakow, Polonia, 30-363
        • Aclaris Investigational Site
      • Lublin, Polonia, 20-607
        • Aclaris Investigational Site
      • Nowa Sól, Polonia, 67-100
        • Aclaris Investigational Site
      • Poznan, Polonia, 60-218
        • Aclaris Investigational Site
      • Poznan, Polonia, 60-446
        • Aclaris Investigational Site
      • Poznan, Polonia, 61-397
        • Aclaris Investigational Site
      • Sochaczew, Polonia, 96-500
        • Aclaris Investigational Site
      • Torun, Polonia, 87-100
        • Aclaris Investigational Site
      • Warsaw, Polonia, 04-141
        • Aclaris Investigational Site
      • Wroclaw, Polonia, 52-442
        • Aclaris Investigational Site
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polonia, 30-002
        • Aclaris Investigational Site
    • Lubelski
      • Tomaszów Lubelski, Lubelski, Polonia, 22-600
        • Aclaris Investigational Site
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Polonia, 20-362
        • Aclaris Investigational Site
    • Masovian Voivodeship
      • Nadarzyn, Masovian Voivodeship, Polonia, 05-830
        • Aclaris Investigational Site
    • Mzowieckie
      • Grodzisk Mazowiecki, Mzowieckie, Polonia, 05-825
        • Aclaris Investigational Site
    • Podlaskie Voivodeship
      • Bialystok, Podlaskie Voivodeship, Polonia, 15-351
        • Aclaris Investigational Site
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, Polonia, 40-282
        • Aclaris Investigational Site
    • Warm.Maz.
      • Elblag, Warm.Maz., Polonia, 82-300
        • Aclaris Investigational Site
    • Warmińsko-Mazurskien
      • Olsztyn, Warmińsko-Mazurskien, Polonia, 10-117
        • Aclaris Investigational Site
    • Wielkopolska
      • Poznan, Wielkopolska, Polonia, 61-113
        • Aclaris Investigational Site
    • California
      • El Cajon, California, Stati Uniti, 92020
        • Aclaris Investigational Site
      • Encino, California, Stati Uniti, 91436
        • Aclaris Investigational Site
      • La Jolla, California, Stati Uniti, 92093
        • Aclaris Investigational Site
      • Palm Desert, California, Stati Uniti, 92260
        • Aclaris Investigational Site
    • Florida
      • Tampa, Florida, Stati Uniti, 33613
        • Aclaris Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73103
        • Aclaris Investigational Site
    • Pennsylvania
      • Duncansville, Pennsylvania, Stati Uniti, 16635
        • Aclaris Investigational Site
    • Tennessee
      • Jackson, Tennessee, Stati Uniti, 38305
        • Aclaris Investigational Site
    • Texas
      • Cypress, Texas, Stati Uniti, 77429
        • Aclaris Investigational Site
      • Mesquite, Texas, Stati Uniti, 75150
        • Aclaris Investigational Site
      • San Antonio, Texas, Stati Uniti, 78229
        • Aclaris Investigational Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Able to comprehend and be willing to sign the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved participant ICF prior to administration of any study-related procedures.
  • Diagnosis of adult-onset RA as defined by the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria.
  • Have active moderate to severe RA at Screening.
  • A minimum of 12 weeks on MTX with a stable MTX dose.

Exclusion Criteria:

  • Current acute or chronic immunoinflammatory disease other than RA which may impact the course or assessment of RA.
  • Uncontrolled non-immunoinflammatory disease that may place the participant at increased risk during the study or impact the interpretation of results (eg, previous malignancy, recurrent infection, previous venous thromboembolism).
  • Participant has experience with > 2 biologics, > 1 JAK inhibitor, or a combination of 1 biologic experience and 1 JAK inhibitor.
  • Currently receiving corticosteroids at doses > 10 mg/day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of screening.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: ATI-450 20 mg BID plus Methotrexate

ATI-450 20 mg oral tablet twice daily (BID) with a stable weekly dose of methotrexate for 12 weeks

15 mg to 25 mg weekly

Oral, small molecule MK2 inhibitor

Altri nomi:
  • zunsemetinib
Sperimentale: ATI-450 50 mg BID plus Methotrexate

ATI-450 50 mg oral tablet BID with a stable weekly dose of methotrexate for 12 weeks

15 mg to 25 mg weekly

Oral, small molecule MK2 inhibitor

Altri nomi:
  • zunsemetinib
Comparatore placebo: Placebo plus Methotrexate

Placebo oral tablet BID with a stable weekly dose of methotrexate for 12 weeks

15 mg to 25 mg weekly

Placebo tablet manufactured to match ATI-450 in appearance

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants Achieving ACR20 at Week 12
Lasso di tempo: Week 12

Participants achieving American College of Rheumatology (ACR) 20 (responders) were defined as having ≥20% improvement in both the number of swollen and tender joints (66/68 joint counts) and ≥20% improvement in ≥3 of the following 5 measures: Patient's Global Assessment of Disease Activity (VAS), Patient's Assessment of Arthritis Pain (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician's Global Assessment of Disease Activity (VAS), and acute phase reactant as measured by hsCRP.

Model-based estimates and 95% confidence intervals (CIs) were produced.

Week 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Concentrazioni di ATI-450 e Metabolita (CDD-2164)
Lasso di tempo: 2 ore dopo la dose nei giorni 1, 8 e 85
2 ore dopo la dose nei giorni 1, 8 e 85
Percentage of Participants Achieving ACR50 at Week 12
Lasso di tempo: Week 12

Participant achieving ACR50 (responders) were defined as having ≥50% improvement in both the number of swollen and tender joints (66/68 joint counts) and ≥50% improvement in ≥3 of the following 5 measures: Patient's Global Assessment of Disease Activity (VAS), Patient's Assessment of Arthritis Pain (VAS), HAQ-DI, Physician's Global Assessment of Disease Activity (VAS), Acute phase reactant as measured by hsCRP.

Model-based estimates and 95% CIs were produced.

Week 12
Percentage of Participants Achieving ACR70 at Week 12
Lasso di tempo: Week 12

Participants achieving ACR70 (responders) were defined as having ≥70% improvement in both the number of swollen and tender joints (66/68 joint counts) and ≥70% improvement in ≥3 of the following 5 measures: Patient's Global Assessment of Disease Activity (VAS), Patient's Assessment of Arthritis Pain (VAS), HAQ-DI, Physician's Global Assessment of Disease Activity (VAS), Acute phase reactant as measured by hsCRP.

Model-based estimates and 95% CIs were produced.

Week 12
Change From Baseline in DAS28-CRP at Week 12
Lasso di tempo: Baseline, Week 12

The DAS28-CRP consists of a composite score of the following variables: TJC28, SJC28, CRP (hsCRP was used for the purposes of this study), and Patient's Global Assessment of Disease Activity. Interpretation of the DAS28-CRP is on a scale of 0 to 9.4, where <2.6 is considered remission, ≥2.6 to <3.2 is considered low/minimal disease activity, ≥3.2 to ≤5.1 is considered moderate disease activity, and >5.1 is considered high/severe disease activity.

The least square (LS) mean change from baseline in DAS28-CRP at Week 12 was estimated from the Mixed Model Repeated Measures (MMRM) model.

Baseline, Week 12
Percentage of Participants Achieving DAS28-CRP Remission (Score <2.6) at Week 12
Lasso di tempo: Week 12

The Disease Activity Score using 28 Joint Count-C-reactive protein (DAS28-CRP) consists of a composite score of the following variables: TJC28, SJC28, CRP (hsCRP is used for the purposes of this study), and Patient's Global Assessment of Disease Activity. Interpretation of the DAS28-CRP is on a scale of 0 to 9.4, where <2.6 is considered remission, ≥2.6 to <3.2 is considered low/minimal disease activity, ≥3.2 to ≤5.1 is considered moderate disease activity, and >5.1 is considered high/severe disease activity.

Model-based estimates and 95% CIs were produced.

Week 12
Percentage of Participants Achieving DAS28-CRP Low Disease Activity (Score ≤ 3.2) at Week 12
Lasso di tempo: Week 12

The DAS28-CRP consists of a composite score of the following variables: TJC28, SJC28, CRP (hsCRP is used for the purposes of this study), and Patient's Global Assessment of Disease Activity. Interpretation of the DAS28-CRP is on a scale of 0 to 9.4, where <2.6 is considered remission, ≥2.6 to <3.2 is considered low/minimal disease activity, ≥3.2 to ≤5.1 is considered moderate disease activity, and >5.1 is considered high/severe disease activity.

Model-based estimates and 95% CIs were produced.

Week 12
Change From Baseline in HAQ-DI Score at Week12
Lasso di tempo: Baseline, Week 12

The HAQ-DI (standard disability method calculation) was utilized to assess the participant's physical function or disability according to the participant. The HAQ-DI is a 20-item, validated questionnaire used to assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities [errands and chores]). Responses in each functional area are scored from 0 (no difficulty) to 3 (inability to perform a ask in that area). Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3. A lower score demonstrated less disability.

LS mean change from baseline in HAQ-DI score at Week 12 was estimated from the MMRM model.

Baseline, Week 12
Change From Baseline in CDAI Score at Week 12
Lasso di tempo: Baseline, Week 12

The Clinical Disease Activity Index (CDAI) was the sum of 4 outcome parameters:

  • Tender joint count out of 28 joints (TJC28)
  • Swollen joint count out of 28 joints (SJC28)
  • Patient's Global Assessment of Disease Activity; and
  • Physician's Global Assessment of Disease Activity.

Interpretation of the CDAI disease activity was measured on a scale of 0 to 76, where ≤2.8 was considered remission, >2.8 to ≤10 was considered low/minimal disease activity, >10 to ≤22 was considered moderate disease activity, and >22.0 was considered high/severe disease activity.

LS mean change from baseline in CDAI score at Week 12 was estimated from the MMRM model.

Baseline, Week 12
Percentage of Participants Achieving CDAI Remission (Score ≤ 2.8)
Lasso di tempo: Week 12

The CDAI was the sum of 4 outcome parameters:

  • Tender joint count out of 28 joints (TJC28)
  • Swollen joint count out of 28 joints (SJC28)
  • Patient's Global Assessment of Disease Activity; and
  • Physician's Global Assessment of Disease Activity.

Interpretation of the CDAI disease activity was measured on a scale of 0 to 76, where ≤2.8 was considered remission, >2.8 to ≤10 was considered low/minimal disease activity, >10 to ≤22 was considered moderate disease activity, and >22.0 was considered high/severe disease activity.

Model-based estimates and 95% CIs were produced.

Week 12
Percent Change From Baseline in hsCRP Level at Week 12
Lasso di tempo: Baseline, Week 12

Blood samples were evaluated to measure levels of hsCRP.

Baseline, Week 12
Change From Baseline in Short Form Health Survey SF-36 Physical Component Summary (PCS) Score at Week 12
Lasso di tempo: Baseline, Week 12

The PCS is composed of 4 scales of the Short Form-36 Health Status Survey Questionnaire (SF-36) version 2 assessing physical function, role limitations caused by physical problems, bodily pain, and general health. The range of the SF-36 PCS is between 0 and 100, where higher scores represent better physical functioning.

A 2.5 to 5-point change from baseline is established as the minimum clinically-important difference for the PCS in RA participants.

LS mean change from baseline in SF-36 PCS score at Week 12 was estimated from the MMRM model.

Baseline, Week 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue) Score at Week 12
Lasso di tempo: Baseline, Week 12

The FACIT-Fatigue is a 13-item questionnaire that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a 4 point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The total score range is from 0 to 52. The higher the score, the lower the fatigue level.

LS mean change from baseline in FACIT-Fatigue score at Week 12 was estimated from the MMRM model.

Baseline, Week 12

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Ajay Aggarwal, Aclaris Therapeutics, Inc.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 febbraio 2022

Completamento primario (Effettivo)

5 settembre 2023

Completamento dello studio (Effettivo)

11 ottobre 2023

Date di iscrizione allo studio

Primo inviato

18 febbraio 2022

Primo inviato che soddisfa i criteri di controllo qualità

4 marzo 2022

Primo Inserito (Effettivo)

15 marzo 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi